Anzeige
Mehr »
Login
Samstag, 18.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Letzte Chance, bevor die Bohrer dieses "Monster"-Vorkommen bei einem 13-Millionen-Unternehmen ansteuern
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
243 Leser
Artikel bewerten:
(1)

Sound Physicians Announces Transformative Transaction to Increase Liquidity and Financial Flexibility; Aims to Drive Growth as the Physician Services Partner of Choice

Finanznachrichten News

Proactively bolsters liquidity with comprehensive debt restructuring and $124 million of new capital; Enters into transaction with overwhelming majority of key partners in capital structure; Momentum follows recent leadership appointments as Company builds a world-class leadership team across key disciplines to advance strategic initiatives.

NEW YORK, NY / ACCESSWIRE / May 21, 2024 / Sound Physicians (the "Company"), a leading provider of physician services and value-based care within the acute setting, today announced a successful refinancing with its lenders to provide access to an additional $124 million of capital (the "Transaction"), which will substantially reinforce the Company's financial position and bolster the Company's operations as one of the largest providers of physician services in the U.S. The new capital will provide substantial runway for the Company to invest in operations and innovation, drive growth, and enhance physician support.

In addition to the new money, the Transaction provides material discount on the pre-Transaction indebtedness and an extension of maturities of the Company's loan facilities until 2028, at the earliest - a strong signal that Sound Physicians' key financial partners continue to support the Company's long-term growth and vision.

The Company reached agreement with lenders representing approximately 85% of the existing first-lien secured debt (including 100% of the existing revolving lenders) and approximately 89% of the existing second-lien secured debt, and with its equity holders, including Summit Partners. The Company is now soliciting its remaining lenders to participate in the Transaction prior to closing and these discussions are ongoing.

"We are pleased to take this important step toward strengthening our balance sheet, a key component of Sound Physicians' growth and transformation," said Jeff Alter, CEO for Sound Physicians. "As one of the most respected medical groups in the U.S. and the practice of choice for over 4,000 clinicians, we are now better placed to meet the needs of our hospital partners and clinicians.

"With additional capital, financial flexibility and runway, a strengthened and experienced leadership team, and the support of our financial partners, Sound Physicians is poised to be an industry leader and continue growing into the coming years," Alter said.

About Sound Physicians

As a physician-founded and led multispecialty medical group, our promise is to bring better to the bedside with our more than 4,000 physicians, advanced practice providers, CRNAs, and nurses practicing community-based medicine in 400-plus hospitals across 45 states. With specialties in emergency and hospital medicine, critical care, anesthesia, and telemedicine, our partners have benefited from Sound's 23 years of experience innovating and leading through an ever-changing healthcare landscape - with patients at the center of our universe. www.soundphysicians.com

Contact Information

Anni Lange
Vice President of Communications and Marketing
alange@soundphysicians.com

SOURCE: Sound Physicians

.

View the original press release on newswire.com.

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.